Patient Resources: COVID-19 and Participation in Clinical Trials
The work to fight disease has always been about the patient. It always will be.
The work to fight disease has always been about the patient. It always will be.
COVID-19 Doesn’t Play Fair: What We Need to Understand About Racial Disparities
Hong Liu, PhD, Making Chicago a Healthier City for Asian Americans
Dorelia Rivera talks about health disparities, a career in advocacy and saving her daughter’s life
Roslyn Daniels, Black Health Matters Founder and President, on Health Disparities and Exciting Communities About Health
Patient Perspective: COVID-19, Community, and Plea for Equitable Participation in Clinical Trials
We Should Not Be Surprised: COVID-19 Disparities Lay Bare What’s Been There All Along
Patient Perspective: The Forgotten and the Pandemic of 2020
Getting the Word Out About Prostate Cancer with Entrepreneur, Engineer, Advocate and Survivor Thomas Farrington
Communicating the Value of Clinical Trials to Underserved Minority Communities
Through the Patient Lens: The Patient’s New Normal in Society’s New Abnormal
Patient Perspective: My Clinical Trial Was Cancelled Due To COVID-19
The Patient Perspective: Facing COVID-19 with Research, Action, and Hope
Raise Your Voices: Social Network Provides Safe Place for Patients to Share Stories and Influence Research
WCG: Advocating for Patients in a time of COVID-19
Patient Perspective: How COVID-19 is Helping Everyone Experience Life as a Patient
Bringing Clinical Trials Closer to Home: Smaller, Local Sites Build Trust & Provide Access to Local Communities
There is Value to Patients When Independent Sites Offer Clinical Trials
Turning Passion Into a Career: Insights from a Physician and Industry Medical Director of AbbVie Pharmaceuticals, Charlotte Owens, MD, FACOG
It’s all about the trust: Authentic community engagement key to diverse trial enrollment
Health Disparities and COVID-19 in Minority Communities
Quickly sift through hundreds of thousands of clinical trials to find the right match.
CenterWatch is a powerful search engine that matches your personal data to ongoing clinical trials: COVID-19 trials and hundreds of thousands of ongoing trials finding treatments for other serious disorders.
Here’s how CenterWatch works:
Note: WCG CenterWatch strongly urges you to conduct this search—and others like it—in counsel with your caregivers.
There is a lot of potentially confusing and conflicting information about COVID-19. Reliable and informative resources include:
Centers for Disease Control and Prevention
Your study coordinator should be able to speak to these and other common questions:
The following is essential information at a patient level:
It is important to maintain your clinical trial study visit schedule. Please contact your study coordinator and/or study site with any questions regarding how on-time visits will take place, whether in person or on line.
It is important for you to notify your study coordinator if you are unable to make an appointment. The coordinator can assist you with scheduling another appointment and/or help with travel arrangements if needed. However, we strongly encourage you to try to attend all of your regularly scheduled study visits.
Whether screening for a particular trial is continued or placed on hold will likely depend on the research organization, the local effect of the pandemic, any applicable mandates/policies, and the availability of people and resources to carry out the procedures necessary for that visit. While many clinical trials are being placed on hold, some are moving forward if they are considered essential (e.g. COVID-19 trials, potential life-saving studies, or those with direct benefit that outweigh the risks of visiting the site in person).
Best advice: call your Investigative Site and speak to your research coordinator.
Highly regarded organizations including the National Health Council, NIH, and FasterCures list hundreds of advocacy groups. Googling a specific disease may turn up an advocacy group. Bear in mind that each group has its own mission. It is important to find a group that meets one’s specific needs.
Use WCG CenterWatch iConnect, a search engine that matches patients to the right clinical trial for their needs. CenterWatch iConnect pairs an easy-to-use proprietary search engine with a database of all ongoing COVID-19 clinical trials, plus hundreds of thousands of other trials under way worldwide. View COVID-19 Trials
Patient advocacy groups are a trusted source for persons seeking clinical trials as well as those already enrolled. During the COVID-19 crisis, pharmaceutical sponsors and study sites also are encouraged to join advocacy-sponsored discussions. First, it’s a way to hear important questions and concerns they might miss otherwise. Second, it can help study teams develop communications throughout this crisis that are patient-friendly and meaningful to patients and their families alike.
Many advocacy groups are convening daily and weekly informational webinars, discussions, and question and answer sessions. These communications with others living with your disease can be quite comforting during uncertain times. You can learn more about such offerings on the advocacy groups’ websites.
If you already had a serious condition and now are concerned about COVID-19 too, chances are your advocacy group has information on their website of help to people like you. Plus, they often have staff who can answer questions person-to-person, provide direct help, guide you to help you can get on your own, and steer you to sources of trustworthy advice.
You can also search using your web browser for other advocacy groups, using the name of the disorder you are interested in as the main search term.
Find out what resources are available to your patient participants. It is important to trial participants to hear which support systems you recommend. It can be important to the success of your study too.
Listen in to WCG’s webinar series for front-line clinical trial professionals combating COVID-19. Top experts (doctors, scientists, medical ethicists, patient advocates and more) hash out the promise and the problems of cutting-edge drugs, therapies and modalities while you watch.
[8/19]The problem of the spread of scientific misinformation is very real. We’ve probably all seen stories on social media about COVID-19, or anonymous testimonies from alleged healthcare providers, some of which seem obviously untrue. But we can’t dismiss the impact that misinformation is having on our ability to combat COVID-19, in terms of mistrust of the scientific community, resistance to following COVID-19 precautions, hesitancy to participate in clinical trials and predicted concerns about wide-spread agreement to COVID-19 vaccine use. In this webinar, the speakers will:
[8/5] The COVID-19 pandemic has brought accessibility to scientific and clinical trial data and information to the general public. But with this eagerness for scientists to share and for media to amplify new information, sometimes even before it has been vetted by other scientists, we also have ethical challenges. In this webinar, our expert bioethicist guests will discuss:
[7/22] There is so much discussion going on across all of clinical research – operations, regulatory, compliance and patient advocacy as it relates to how we’re all handling the COVID-19 environment. We’ve seen adaptations to telemedicine, shipping study drugs to participants, remote endpoint assessments and laboratory testing collected locally or at home. But how many of those changes will stick when the “new normal” comes? The changes that allowed studies to continue through COVID are many of the ones that patients have been asking for to decrease participant burden and expense, and to make trial participation available to a broader and more diverse population. In this webinar, we’ll discuss:
[7/8] The resumption of Clinical Research is underway, with new precautions and procedures in place for the protection of research participants and research staff. As institutions resume clinical research and initiate new clinical trials, there is growing stress on the internal resources necessary to support key study-related activities for both COVID-19 and non-COVID-19 trials – including data entry, monitoring, and patient enrollment and engagement. There is growing concern that sites, CRAs and other critical resources will be unable to absorb the volume of work required in the short-term to make up for lost time.
In this webinar, we will:
[6/24] As clinical trials shift quickly and necessarily from in-person to hybrid trials, remote visits, and virtual experiences and support, new opportunities and challenges emerge. While the industry figures out how to best navigate these new challenges, and much remains unresolved, we do know this: Sites and sponsors will be recalibrating everything, especially contract terms and budgets for either new components of trials or changes to clinical research. Site budgets for ongoing studies will need to be recalculated, amended and renegotiated, and contracts and budgets for new studies will have new considerations. In this webinar, we’ll explore:
[6/3] COVID-19 and the effort to develop treatments and vaccines for COVID-19 have brought awareness of clinical trials into the public view like never before. What impact is that discussion having on the public’s understanding of clinical trials as part of the drug development process? In addition, there’s been extensive conversation about ensuring COVID-19 treatment studies include an appropriately representative population. How can we advance this important discussion to achieve diversity in research study enrollment?
In this webinar we:
[5/27] More clinical trials are conducted for cancer than for other therapeutic areas, and these trials often include participants who have exhausted the available treatment options. So when COVID-19 forced a re-assessment of ongoing and upcoming studies, patients and care providers were placed in a difficult situation. We’ll talk to a leading cancer researcher and a patient who was in screening for a new clinical trial, about the present and future of oncology clinical trials.
Our expert speakers discuss:
[5/20] In this webinar, we turn our focus to the challenges unique to our innovative colleagues in the emerging biopharma space. With smaller and focused-pipeline organizations making up over 50% of clinical trials activity pre-COVID-19, these sponsors represent the potential for enormous advances in development, but also shoulder the challenges of keeping projects moving in highly concentrated pipelines during this time. Our expert speakers discuss:
We’ll speak with leaders from emerging biopharma organizations with assets in different therapeutic areas and in various phases of development and commercialization; and about the evolving resources that address biopharma needs during this time.
[5/13] In this webinar, our expert speakers turn their attention to challenges of doing research on the COVID-19 pandemic. They discuss:
[5/6] In this webinar, we turned our focus to the realities of restarting clinical trials by examining WCG data spanning the clinical trials ecosystem. We talked to leaders at research sites to understand their key issues and we’re helping sponsors understand what they should be aware of as they prepare to re-engage. We speak with our expert panel about the following:
[4/29] In this webinar, our expert, Ken Getz of Tufts CSDD, explores 3 facets of this transitional period:
[4/22] In this webinar, our panel of experts discuss what you need to know about the impact of COVID-19 on your clinical trials:
[4/15] In this webinar, our panel of experts discuss what you need to know about the impact of COVID-19 on your clinical trials:
[4/8] Our panel of experts discuss what you need to know about the impact of COVID-19 on your clinical trials:
[4/1] Our panelists discuss best practices for:
[3/25] Our panelists cover how clinical sites and institutions are making decisions about what research should continue during COVID-19, what resources site teams are utilizing to shift study visits to virtual and remote assessments, and what changes are being made to protocols based on site policies and precautions. Also presented is the participant perspective: how we can manage fear, change, and messages about “non-essential” research priorities.
[3/18] From protocol amendments to participant recruitment and retention, the impact of COVID-19 could be enormous. What can you do to minimize the disruption to your ongoing, or upcoming, clinical trial? Our panel of experts from NYU Langone Medical Center and WCG discuss ways to reduce the impact of this pandemic on your studies to keep them on track.
[3/13] In this webinar, experts from the FDA and Massachusetts General Hospital discuss what we know, and don’t know, about the nature and epidemiology of COVID-19, what’s happening as we work to develop vaccines and therapeutic agents, and how health care institutions are preparing for COVID-19 across different divisions.
key takeaways from Dr. Paul Biddinger